Aspirin 25mg (immediate-release), dipyridamole 200mg (extended-release); caps. Dipyridamole inhibits the uptake of adenosine into platelets, endothelial cells and erythrocytes in vitro and in vivo ...
ASHP Therapeutic Position Statement on the Daily Use of Aspirin for Preventing Cardiovascular Events
ASHP believes that patients at risk for CHD and without contraindications to aspirin therapy should use aspirin to prevent cardiovascular events. It is an effective, low-cost, and relatively safe ...
The relative benefit of therapeutic anticoagulation in patients ... examining the relative efficacy and safety of warfarin and aspirin in patients with reduced ejection fraction (EF) in the ...
Objectives The use of aspirin to prevent cardiovascular disease in vasospastic angina (VSA) patients without significant stenosis has yet to be investigated. This study aimed to investigate the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results